Printer Friendly

BioVeris licenses vaccine portfolio from Baxter.

BioVeris Corporation (Gaithersburg, MD) completed a Technology License Agreement with Baxter Healthcare Corporation for exclusive patent rights to a broad portfolio of vaccine candidates. Vaccines covered by the Agreement include those for the prevention of diseases caused by Group A streptococci, Group B streptococci, Pneumococci, Group B meningococci, anthrax bacilli and urinary tract infection (UTI) associated E. coli.

Under the Agreement, BioVeris receives exclusive rights to patents or know-how related to the manufacture, production, use and commercialization of the vaccine candidates. The company paid a license issue fee and may also make additional future payments for patent costs, milestone fees for initiating and completing human clinical trials and receiving regulatory approvals. The company is also required to pay royalties on product sales and beginning in 2010, is required to pay a minimum annual royalty that is creditable against any other milestone payments and royalties.

The vaccine portfolio covered by the agreement is based on a conjugate technology platform and also includes recombinant protein antigens. The vaccine candidates are expected to complement and expand the existing intellectual property and vaccine candidates at BioVeris, which now has additionl comprehensive candidates for vaccines against bacterial meningitis, including that of streptococcal, pneumococcal and meningococcal origin.

BioVeris' vaccine candidate portfolio addresses the need for vaccines against different organisms, including group A streptococci (of strep throat, impetigo, flesh-eating bacteria and streptococcal toxic shock syndrome), group B streptococci (of sepsis, meningitis, and pneumonia in newborns and adults), group B meningococci (of sepsis, meningitis, and pneumonia at any age), and E. coli (of UTI, predominantly for women). In addition, the vaccine candidate for disease caused by anthrax bacilli may provide a safer and better anthrax vaccine based on a recombinant protective antigen. Each of these vaccines could be candidates for entry into billion dollar global markets.

BioVeris is a global integrated health care company developing proprietary technologies in diagnostics and vaccinology. The company is dedicated to the commercialization of innovative products and services for healthcare providers, their patients and their communities.

BioVeris Corporation

+1-301-869-9800

www.bioveris.com
COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Jul 1, 2005
Words:339
Previous Article:Misonix's Sonora medical unit receives ultrasound patent.
Next Article:Arena granted patent for drug screening methods related to Ortho McNeil collaboration.
Topics:


Related Articles
Cell Genesys exclusively licenses technology for liver-directed Aav gene therapy from University of Washington.
Baxter obtains United States patent.
BioVeris completes agreements With University of Massachusetts at Amherst secures exclusive rights to unique Chlamydia vaccine candidate targeting...
Emergent acquires vaccine company.
LIPOXEN SIGNS $75MIL PACT TO DEVELOP BLOOD CLOTTING FACTORS.
BAXTER'S ACHIEVED RECORD SALES/EARNINGS IN 2006.
Roche expands research offerings.
BAXTER ACHIEVES RECORD SALES AND EARNINGS FOR FULL-YEAR 2007.
Baxter posts first-quarter earnings gain of 6%.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters